CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma.

Ruonan ZhangJie WangYu DuZe YuYihan WangYixiao JiangYixin WuTing LeZiqi LiGuoqiang ZhangLei LvHaijie Ma

Published in: Journal for immunotherapy of cancer (2023)

Targeting CDK5 can synergize with PD-1 blockade to suppress HCC growth, which may have clinical benefits. Our study reveals a unique regulation of the degradation of PD-L1 in HCC, and provides an attractive therapeutic target, a potential drug, and a new prognostic marker for the clinical treatment of HCC.

Keyphrases

cell cycle
public health
papillary thyroid
cell death
emergency department
cancer therapy
drug delivery
squamous cell